Indaptus Therapeutics
INDP
25 hedge funds and large institutions have $2.71M invested in Indaptus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 10 closing their positions.
131% more call options, than puts
Call options by funds: $30K | Put options by funds: $13K
1.79% less ownership
Funds ownership: 17.29% → 15.5% (-1.8%)
24% less funds holding
Funds holding: 33 → 25 (-8)
36% less capital inflows, than outflows
Capital inflows: $466K | Capital outflows: $727K
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETF Managers Group
Summit,
New Jersey
|
+$149K |
| 2 |
Phoenix Financial
Givatayim,
Israel
|
+$67.6K |
| 3 |
Two Sigma Securities
New York
|
+$8.28K |
| 4 |
GSA Capital Partners
London,
United Kingdom
|
+$5.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Taylor Frigon Capital Management
Scottsdale,
Arizona
|
-$302K |
| 2 |
ARK Investment Management
St. Petersburg,
Florida
|
-$105K |
| 3 |
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$101K |
| 4 |
Boothbay Fund Management
New York
|
-$48K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$35K |
INDP Hedge Fund Activity: Q4 2019 in Review
25 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2019, worth a combined $2.71M — down 34% from $4.08M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of INDP and 2 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was ETF Managers Group, adding an estimated $149K. The largest seller was Taylor Frigon Capital Management, exiting entirely with an estimated $302K sold.
- 25 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2019, down from 33 in Q3 2019.
- Funds reported $2.71M of Indaptus Therapeutics stock for Q4 2019, down 34% quarter-over-quarter.
- 2 funds opened new Indaptus Therapeutics positions in Q4 2019 and 10 closed out, a net change of -8 holders.
- The largest Indaptus Therapeutics buyer in Q4 2019 was ETF Managers Group, an estimated $149K added.
- The largest Indaptus Therapeutics seller in Q4 2019 was Taylor Frigon Capital Management, an estimated $302K sold.
Based on aggregated 13F filings for Q4 2019.